文献速递血栓与止血

比较血友病A女性的一期法与显色法检测结果及其与出血表型和遗传变异的差异

Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A.
PubMed 文献 · J Thromb Haemost · 2024-11-12

本研究回顾性分析了本中心64例血友病A女性的数据,比较一期法与显色法测定的FVIII:C水平及检测差异与出血表型和基因突变的关系。结果显示52%患者ISTH-BAT评分异常,检测差异存在且直接差异多于反向差异,仅凭一种检测方法会导致11例(17%)误诊和1例(1.5%)严重度分级错误。未发现遗传变异与FVIII:C水平或出血表型的关联。

要点

  • 52%的血友病A女性ISTH-BAT评分异常,FVIII:C<40 IU/dL者异常率更高。
  • 一期法与显色法检测差异存在,直接差异多于反向差异。
  • 仅凭一种检测方法,11例(17%)误诊,1例(1.5%)严重度分级错误。

核心结论

  • 本研究强调评估血友病A女性出血表型的重要性,并首次专门记录女性血友病A中检测差异的患病率,该差异可导致诊断和严重度分级不准确。

研究设计与样本

  • 回顾性分析本中心64例血友病A女性的数据,经中心机构审查委员会批准,采用描述性统计、卡方检验、Fisher精确检验和Bland-Altman图分析。

主要发现

  • 52%患者ISTH-BAT评分异常(FVIII:C<40 IU/dL:一期法72%、显色法73%;FVIII:C≥40 IU/dL:一期法41%、显色法45%),成人及月经初潮后患者更常见。
  • 检测差异存在,直接差异多于反向差异。
  • 仅基于一种检测结果,11例(17%)患者会被错误诊断,1例(1.5%)患者会被错误分配血友病严重度。
  • 未发现遗传变异与FVIII:C水平及出血表型的关联。

局限性

  • 原文指出需要未来更大规模、多中心的研究来验证本研究发现,以帮助制定关于适当使用检测方法以实现准确诊断的建议,并进一步阐明遗传变异与出血表型及检测差异的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing evidence in females with hemophilia A has shown significant bleeding symptoms. Accurate factor (F) VIII activity (FVIII:C) measurement is essential to assign correct diagnosis and severity. Assay discrepancies reported in male patients with hemophilia A are not well studied in females. OBJECTIVES: Our research sought to assess the association of FVIII:C levels by one-stage versus chromogenic assays and the assay discrepancy with bleeding phenotype and genetic mutation in females with hemophilia A. METHODS: Data from 64 females with hemophilia A from our center were reviewed with center's institutional review board approval. Descriptive statistics, chi-squared, Fisher's exact, and Bland-Altman plot analysis were applied. RESULTS: Abnormal International Society on Thrombosis and Haemostasis bleeding assessment tool score was seen in 52% (FVIII:C <40 IU/dL: 72%/73%; FVIII:C ≥40 IU/dL: 41%/45%; by one-stage and chromogenic assays, respectively), more often in adults and postmenarchal patients. Assay discrepancies were present, direct more often than inverse. Based on one assay result only, 11 (17%) patients would have been incorrectly diagnosed and 1 (1.5%) patient would have been assigned incorrect hemophilia severity. No associations of genetic variants with FVIII:C levels and bleeding phenotype were found. CONCLUSION: Our study emphasizes the importance of evaluating female patients with hemophilia A for bleeding phenotype. Our study is the first to document prevalence of assay discrepancies exclusively in females with hemophilia A, which can lead to inaccurate diagnosis and severity assignment. Future larger, multicenter studies are needed to validate our findings, to help develop recommendations regarding the appropriate use of assays for accurate diagnosis and to further elucidate the association of genetic variants with bleeding phenotype and assay discrepancies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Srivaths L, Larson J, Saroukhani S, et al. Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A. J Thromb Haemost. 2024. PMID: 39536816. doi:10.1016/j.jtha.2024.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。